Loading organizations...
Solu Therapeutics is pioneering a new therapeutic modality to redefine what is possible and transform patient lives by developing innovative antibody therapeutics.
Solu Therapeutics has raised $72.0M across 2 funding rounds.
Solu Therapeutics has raised $72.0M in total across 2 funding rounds.
Solu Therapeutics has raised $72.0M across 2 funding rounds. Most recently, it raised $41.0M Series A in April 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2025 | $41M Series A | — | John Hamer, Dcvc (data Collective), Longwood Fund | Announced |
| Jul 1, 2023 | $31M Seed | Longwood Fund, Saints Capital | John Hamer, Dcvc (data Collective) | Announced |
Solu Therapeutics is a clinical-stage biotechnology company pioneering next-generation therapeutics that selectively eliminate disease-driving cells in cancer, immunology, and autoimmune diseases. Their proprietary platforms, CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera), combine small molecule targeting with antibody-based therapies to enhance specificity, efficacy, and safety. Solu serves patients with unmet medical needs in oncology and inflammatory diseases by developing medicines that target previously inaccessible cell surface proteins, including GPCRs and ion channels. The company is advancing its lead candidate, STX-0712, currently in Phase 1 trials for chronic myelomonocytic leukemia, and has demonstrated rapid drug development capabilities with a strong pipeline progressing toward clinical stages[1][2][3][4].
Founded in May 2023 in Boston, Solu Therapeutics emerged following an exclusive license acquisition of the CyTAC platform from GlaxoSmithKline (GSK). The founding team comprises experienced biotechnology and drug development professionals who envisioned transforming therapeutic modalities by industrializing a platform that links bifunctional small molecules to proprietary antibodies. Early pivotal moments include the rapid advancement of their lead clinical candidate into Phase 1 trials and securing significant funding, including a $41 million Series A round, which has fueled their growth and pipeline expansion[1][2][3].
Solu Therapeutics is riding the trend of precision medicine and targeted biologics combined with small molecule drugs, addressing the limitations of conventional therapies by enabling selective cell elimination with improved safety profiles. The timing is favorable due to advances in antibody engineering, small molecule chemistry, and growing demand for treatments in oncology and autoimmune diseases. Market forces such as increasing prevalence of chronic diseases and the need for innovative therapies support Solu’s growth. By unlocking novel drug targets like GPCRs and ion channels, Solu influences the biotech ecosystem by expanding the druggable proteome and offering new modalities that may reshape therapeutic strategies across multiple disease areas[1][2][3][4].
Solu Therapeutics is positioned for significant growth as it advances clinical trials and expands its pipeline. Future trends shaping its journey include continued innovation in antibody-small molecule conjugates, precision targeting of immune and tumor cells, and potential expansion into additional therapeutic areas such as pain management. Their influence may evolve through partnerships, licensing, and possibly bringing first-in-class medicines to market that redefine treatment paradigms. Solu’s industrialized platform and rapid development approach could set new standards for efficiency and efficacy in drug discovery, making it a notable player in the biotech landscape moving forward[1][2][3][4].
Solu Therapeutics has raised $72.0M in total across 2 funding rounds.
Solu Therapeutics's investors include John Hamer, DCVC (Data Collective), Longwood Fund, Saints Capital.
